Analytical Data
-
基因名
HLA-A*02:01&B2M&SSX-2(KASEKIFYV) Monomer
- Application
-
别名
HLA-A*0201 & B2M & SSX-2 (KASEKIFYV)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59606.1 (G25-I308)&P61769
-
表达区间
AAA59606.1 (G25-I308)&P61769 (I21-M119)&KASEKIFYV
-
分子量
40-43 kDa and 11 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*02:01 is a highly significant class I major histocompatibility complex (MHC) molecule, playing a critical role in the immune system by presenting peptide antigens to CD8+ T cells. The β2-microglobulin (B2M) is essential for its stability and surface expression, while SSX-2 (KASEKIFYV) is an oncofetal antigen often overexpressed in various tumors, making it a target of interest in cancer immunotherapy. The combination of HLA-A*02:01, B2M, and the SSX-2 peptide provides a unique opportunity to investigate the binding affinity, stability, and immunogenicity of tumor-associated antigens. Studies on this recombinant monomer can enhance our understanding of the mechanisms underlying T-cell activation and recognition of cancer cells. Additionally, elucidating the structural dynamics of this complex could pave the way for the development of novel therapeutic vaccines and T-cell therapies targeting SSX-2-positive tumors. Furthermore, this research can contribute to the overall field of personalized cancer immunotherapy, where understanding individual T-cell responses to specific antigen-MHC complexes is crucial for effective treatment strategies. Overall, the HLA-A*02:01/B2M/SSX-2 (KASEKIFYV) recombinant protein serves as a pivotal tool in advancing cancer treatment research and improving outcomes for patients with malignancies expressing this particular antigen.
